Want to see AU:CCO full AI Analyst Report?
Top Page
Fiji Kava Limited
(Sydney:CCO)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.01
â–²(900.00% Upside)
Action:Upgraded
Date:09/06/26
The score is primarily constrained by weak financial performance—ongoing losses, significant cash burn, and a weakened capital structure with negative equity and elevated debt. Valuation is also impaired by negative earnings (negative P/E) and no dividend yield data. Technical analysis contributes little due to missing indicators, resulting in a neutral impact rather than a supportive signal.
Positive Factors
Strong Revenue Scaling
The substantial multi-year increase in revenue indicates that Fiji Kava has achieved meaningful commercial traction and expanded sales of its kava products. Continued top-line scale can improve operating leverage and strengthen the platform for future profitability if margins recover.
Negative Factors
Persistent Losses and Margin Pressure
Deep net losses and the sharp gross-margin deterioration show that revenue growth has not yet translated into a sustainable earnings model. Continued margin weakness could limit reinvestment, require additional funding, and make future profitability dependent on a significant improvement in pricing, costs, or product mix.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Scaling
The substantial multi-year increase in revenue indicates that Fiji Kava has achieved meaningful commercial traction and expanded sales of its kava products. Continued top-line scale can improve operating leverage and strengthen the platform for future profitability if margins recover.
Read all positive factors
Fiji Kava Limited (CCO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.04M
Dividend YieldN/A
Average Volume (3M)17.77M
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue Growth1.01%
EPS Growth18.18%
CountryAU
Employees2
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)<0.01
Shares Outstanding7,042,258,300
10 Day Avg. Volume17,774,369
30 Day Avg. Volume17,774,369
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-19.99
Price to Sales (P/S)1.11
P/FCF Ratio-3.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$16.03M
Fiji Kava Limited Business Overview & Revenue Model
Company Description
The Calmer Co International Limited is a health and wellness enterprise focused on medicinal kava, conducting its operations in Australia, New Zealand, Fiji, and the United States. This company manufactures and distributes noble kava extract produ...
How the Company Makes Money
null...
Fiji Kava Limited Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
28
Negative
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.12M | 8.03M | 4.26M | 1.78M | 2.05M |
| Gross Profit | 828.54K | 3.48M | 2.05M | -1.40M | 236.14K |
| EBITDA | -3.00M | -3.45M | -3.34M | -4.86M | -5.72M |
| Net Income | -3.81M | -3.99M | -3.73M | -5.24M | -5.92M |
Balance Sheet | |||||
| Total Assets | 4.91M | 5.68M | 4.33M | 3.24M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 668.73K | 1.46M | 1.10M | 462.15K | 814.06K |
| Total Debt | 3.88M | 2.31M | 2.21M | 2.35M | 1.78M |
| Total Liabilities | 5.36M | 3.78M | 4.80M | 3.32M | 2.51M |
| Stockholders Equity | -451.34K | 1.90M | -466.84K | -87.53K | 2.28M |
Cash Flow | |||||
| Free Cash Flow | -2.98M | -4.83M | -2.19M | -3.82M | -7.10M |
| Operating Cash Flow | -2.94M | -4.37M | -2.08M | -3.80M | -6.14M |
| Investing Cash Flow | -47.14K | -459.91K | -116.97K | -21.08K | -964.94K |
| Financing Cash Flow | 2.19M | 5.19M | 2.83M | 3.47M | 6.74M |
Fiji Kava Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$13.33M | -1.79 | -88.51% | ― | 11.96% | -81.99% | |
44 Neutral | AU$7.04M | -1.23 | 2884.47% | ― | 1.01% | 18.18% | |
44 Neutral | AU$5.28M | -2.34 | -49.07% | ― | -33.53% | 42.98% | |
41 Neutral | AU$1.61M | -0.38 | -239.37% | ― | ― | ― | |
39 Underperform | AU$16.92M | -5.29 | 1795.70% | ― | 0.72% | -486.96% | |
39 Underperform | AU$6.99M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
AU:CCO
Fiji Kava Limited
―
―
―
AU:EVE
EVE Health Group Limited
0.02
-0.01
-46.67%
AU:NUC
Nuchev Pty Ltd
0.09
-0.06
-43.33%
AU:HCT
Holista Colltech Limited
0.04
-0.06
-59.05%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
<0.01
5.00%
AU:HPC
Hydration Pharmaceuticals Co. Ltd.
0.01
0.00
0.00%
Fiji Kava Limited Corporate Events
The Calmer Co Securities Reinstated to ASX Quotation
Sep 3, 2026
The Australian Securities Exchange has announced that the CCOO security class of The Calmer Co International Limited will be reinstated to quotation, following the company’s compliance with ASX Listing Rule 2.5. This reinstatement means that...
The Calmer Co Options Register Reveals Highly Concentrated Ownership
Sep 3, 2026
The Calmer Co International Limited has disclosed the distribution of holdings for its options expiring on 20 February 2029, priced at $0.002, showing a highly concentrated ownership structure. The report indicates that 176 holders control approxi...
The Calmer Co Reveals Concentrated Ownership in 2029 Options
Sep 3, 2026
The Calmer Co International has released a top holders report for its options expiring in February 2029, priced at $0.002, detailing the ownership structure of this security class. The top 20 option holders collectively own about 66.76% of the 945...
The Calmer Co raises $1.82m to fund kava growth and Coles rollout
Sep 2, 2026
The Calmer Co International Limited has completed its renounceable rights issue, raising $1.82 million before costs and issuing approximately 1.82 billion new shares and 945 million options, with directors and management fully taking up their enti...
The Calmer Co. Details ASX Governance Compliance in Appendix 4G Filing
Aug 31, 2026
The Calmer Co. International Ltd has lodged its Appendix 4G with the ASX for the year ended 30 June 2026, confirming that its corporate governance statement is available on its website and current as of 26 August 2026. The filing outlines complian...
The Calmer Co. to Brief Investors on FY26 Progress and Strategic Priorities
Aug 20, 2026
The Calmer Co. International Limited, a consumer packaged goods company specialising in kava-based and other natural relaxation and sleep-support products, is expanding its footprint in the functional beverage and wellness markets. It distributes ...
ASX Suspends Specific Calmer Co Security Class Over Listing Rule Compliance
Aug 20, 2026
The Australian Securities Exchange has suspended from quotation a specific class of securities in The Calmer Co International Limited, identified by the code CCOO, under Listing Rule 17.3.4. The halt will remain in effect until the company meets t...
The Calmer Co. builds kava supply and global reach on strong FY26 retail growth
Aug 18, 2026
The Calmer Co. International reported strong FY26 performance, highlighted by a 24% quarterly surge in retail sales that made retail its largest revenue channel and set momentum for FY27 growth. The company is leveraging rising global demand for k...
The Calmer Co. Extends Entitlement Offer to Support Growth in Global Wellness Markets
Aug 12, 2026
The Calmer Co. International Limited (ASX: CCO) operates in the natural wellness sector, offering products designed to calm nerves, support mind and muscle relaxation and promote sleep. Its portfolio spans drinking powders, teas, shots, concentrat...
The Calmer Co. Secures Long-Term Pacific Kava Supply to Support Growth
Aug 5, 2026
The Calmer Co. International Limited has signed a long-term Strategic Supply Agreement with a leading Pacific-based supplier of premium noble kava, securing reserved capacity of 10 tonnes per month from Papua New Guinea and Vanuatu. The deal, with...
The Calmer Co Launches Renounceable Rights Offer to Raise A$3.5m
Aug 5, 2026
The Calmer Co International Limited has launched a pro rata renounceable entitlement offer, allowing eligible shareholders to subscribe for one new share for every existing share at an issue price of A$0.001, aiming to raise up to A$3.5 million be...
The Calmer Co. Strikes Strategic Manufacturing Partnership to Scale Global Botanical Extracts
Jul 29, 2026
The Calmer Co. International has signed a binding strategic partnership heads of agreement with Kaiming Agro Processing’s subsidiary Pacific Culture and Heritage to develop a long-term manufacturing alliance for kava, ginger and turmeric CO&...
The Calmer Co. Begins Trading Entitlement Offer Rights on ASX
Jul 29, 2026
The Calmer Co. International Limited has begun trading rights for its renounceable entitlement offer on the ASX under code CCOR, following the announcement of the offer and lodgement of the associated prospectus and documentation. The timetable ou...
The Calmer Co Clarifies Terms of Free-Attaching Options in ASX Capital Raise
Jul 28, 2026
The Calmer Co International Limited has lodged an updated notice with the ASX regarding a proposed pro rata renounceable issue of securities, clarifying that the associated options are free-attaching and carry no issue price. This clarification re...
The Calmer Co. Revises Timetable for A$3.5m Entitlement Offer
Jul 27, 2026
The Calmer Co. International Limited has updated the indicative timetable for its pro-rata renounceable entitlement offer, which is intended to raise up to A$3.5 million from existing shareholders. The offer schedule now spans late July to late Au...
The Calmer Co Unveils Major Renounceable Entitlement Offer
Jul 27, 2026
The Calmer Co International Limited, listed on the ASX under the code CCO, operates in the consumer health and wellness sector, focusing on products designed to support relaxation and stress relief. The company targets retail and investor markets ...
The Calmer Co launches $3.5m renounceable rights issue to fund growth and repay notes
Jul 27, 2026
The Calmer Co International Ltd has announced a pro rata renounceable entitlement offer to raise up to approximately $3.5 million before costs, through a 1-for-1 rights issue priced at A$0.001 per new share with one free attaching option for every...
The Calmer Co Issues New Shares on Option Exercise, Affirms Compliance
Jul 7, 2026
The Calmer Co International Limited, an ASX-listed beverage and wellness company, develops and sells kava-based and other natural products that offer alternatives to alcohol and promote relaxation and sleep. Its products, sold under the Fiji Kava,...
The Calmer Co Seeks Quotation for New ASX Shares
Jul 6, 2026
The Calmer Co International Limited has applied for quotation of 632,988 new ordinary fully paid shares on the ASX, with an issue date of July 3, 2026. The securities arise from the exercise of options or conversion of other instruments, modestly ...
The Calmer Co. Wins Coles Listing for New Fiji Kava FZZR as It Targets U.S. Retail Growth
Jun 23, 2026
The Calmer Co. has secured Coles ranging for its new Fiji Kava FZZR kava product, an innovative effervescent supplement format that can be dissolved, chewed or taken direct-to-mouth and will be regulated as a complementary medicine under Australia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.